DRONTAL CAT XL FILM-COATED TABLETS

Država: Irska

Jezik: angleščina

Source: HPRA (Health Products Regulatory Authority)

Kupite ga zdaj

Lastnosti izdelka Lastnosti izdelka (SPC)
13-05-2017

Aktivna sestavina:

PRAZIQUANTEL PH. EUR., PYRANTEL EMBONATE

Dostopno od:

Bayer Limited

Koda artikla:

QP52AA51

INN (mednarodno ime):

PRAZIQUANTEL PH. EUR., PYRANTEL EMBONATE

Odmerek:

30/345

Farmacevtska oblika:

Tablets

Tip zastaranja:

CAM-Companion Animal Medicine

Terapevtska skupina:

Feline

Terapevtsko območje:

Praziquantel, combinations

Terapevtske indikacije:

Endoparasiticide

Status dovoljenje:

Authorised

Datum dovoljenje:

2004-08-06

Lastnosti izdelka

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Drontal Cat XL Film-coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Film-coated tablet.
White to yellowish, ellipsoid, biconvex, unscored tablet.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of gastrointestinal roundworms and tapeworms:
_Toxocara cati, Toxascaris leonina, Dipylidium caninum,_
_Taenia taeniaeformis._
4.3 CONTRAINDICATIONS
Do not use simultaneously with piperazine compounds.
Not intended for use in kittens less than 6 weeks of age.
Until sufficient studies have been performed with this combination, do
not use during pregnancy.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Fleas serve as intermediate hosts for one common type of tapeworm –_
Dipylidium caninum_. Tapeworm infestation is
certain to re-occur unless control of intermediate hosts such as
fleas, mice etc is undertaken.
As a precautionary measure to prevent the establishment of_ E.
multilocularis_ in the UK or Ireland, it is recommended
that all cats entering the country be treated with praziquantel.
Each tablet contains:
ACTIVE SUBSTANCES
Pyrantel embonate
345
mg
Praziquantel
30
mg
EXCIPIENTS
Titanium dioxide E171 (colouring agent)
2.60 mg
For a full list of excipients see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_6_
_6_
_2_
_4_
_p_
_a_
_
                                
                                Preberite celoten dokument